Results 1 to 10 of about 14,267 (224)

Rituximab in Pemphigus Foliaceous With Autoantibodies Against Both Desmoglein 1 and Desmoglein 3 [PDF]

open access: yesEuropean Journal of Dermatology, 2011
ejd.2011.1288 Auteur(s) : Rodrigo CARVALHO1 rodrigoaraujocarvalho@gmail.com, Paula MAIO1, Daniela CUNHA1, Isabel FREITAS1, Ana AFONSO2, Jorge CARDOSO1 1 Department of Dermatology and Venereology, Curry Cabral Hospital, Lisbon, Portugal 2 Department of Pathology, Curry Cabral Hospital, Lisbon, Portugal Reprints.: R. CARVALHO Pemphigus foliaceous (PF) is
Afonso, A   +5 more
core   +2 more sources

Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center

open access: yesMedicina
Background and Objectives: Rituximab (RTX) has been the predominant treatment for autoimmune bullous diseases (AIBDs). The objective of this research was to assess the advantages and safety characteristics of RTX treatment in individuals with AIBD.
Maciej Marek Spałek   +3 more
doaj   +1 more source

The desmosome and pemphigus [PDF]

open access: yes, 2008
Jens Waschke   +347 more
core   +1 more source

Pemphigus foliaceus presenting with violaceous, painful nodules and an aberrant auto-antibody expression in a Latino patient

open access: yesJAAD Case Reports, 2021
Jeffrey N. Li, BS, BBA   +4 more
doaj   +1 more source

NOMENCLATURE OF THE DESMOSOMAL CADHERINS [PDF]

open access: yes, 1993
BUXTON, RS   +10 more
core   +1 more source

Desmoglein 2 mutant mice develop cardiac fibrosis and dilation [PDF]

open access: yes, 2011
Claudia A. Krusche   +9 more
core   +1 more source

Kallikrein related peptidases 7 and 10 and their substrate desmoglein 3 are upregulated in early stage pancreatic cancerous lesions. [PDF]

open access: yesSci Rep
Eisenhauer J   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy